Pubmed Biomarker Relation Odds
(95% CI)		 P-value Description
34731191 TET1 OS p=0.015 Patients with EC with a lower score (≤20) had worse OS than those with a higher score (>20)
34339705 TMEFF2 OS p=0.004 Positive TMEFF2 expressing patients had poor 5 year OS rates
30556848 LncRNA FER1L4 survival HR=2.782 95% CI: 1.144-5.123 p=0.004 Multivariate analysis of the prognosis factors confirmed that low FER1L4 expression was a significant independent predictor of poor survival in EC
30521558 Jag1 Notch pathway survival HR = 0.48, 95% CI 0.23–0.97 p=0.042 Jag1 positivity conferred reduced mortality risk
30521558 Patched-1 DFS HR = 2.04, 95% CI 1.05–3.96 p = 0.032 Regarding the Hedgehog pathway, Patched-1 positivity independently conferred increased risk for relapse
30521558 Notch2 survival HR = 1.93, 95% CI 0.90–4.13 p = 0.093 In comparison to Jag1, Notch2 exhibited a trend in the opposite direction with respect to relapse
30377136 MMP20 survival p=0.019 An elevated MMP20 protein expression was positively associated with inversely correlated with the survival time of the patients
30377136 MMP20 survival p=0.067 The Cox regression model analysis showed that an increased MMP20 expression was an independent predictor of a poor prognosis of the patients with endometrial carcinoma
30372483 CD44 OS p=0.035 High-level CD44 expression was found in 35.4% (40/113) of the cases and was also correlated with a poor overall survival rate
30372483 ALDH1 OS p=0.035 A high level of expression of ALDH1 was found in 44.25% (50/113) of the endometrial cancer samples, which was significantly correlated with a poor overall survival rate
30372483 ALDH1 and CD44 OS p=0.013 A simultaneous high expression of both markers was correlated with an extremely poor overall survival
30282081 lymphocyte infiltration (LI) OS p=0.004 Weak LI was independent worse prognostic factor for OS
34339705 SMOC-2 OS p<0.001 SMOC-2 high expression was positively correlated with overall survival
30282081 lymphocyte infiltration (LI) PFS p=0.022 Weak LI was independent worse prognostic factor for PFS
30282081 lymphocyte infiltration (LI) PFS hazard ratio [HR], 3.76; 95% CI 1.76–8.83 p<0.001 Weak LI was independent worse prognostic factor for PFS
30282081 lymphocyte infiltration (LI) OS HR 6.13; 95% CI 1.73– 29.29 p=0.004 Weak LI was independent worse prognostic factor for OS
29980240 L1CAM DFS HR 2.53, CI95% 1.42–4.51 p=0.002 At multivariate analysis only L1CAM was confirmed as significant predictors of worse DFS
29980240 L1CAM DFS p=0.002 Higher expression of L1CAM was present in tumor patients with lower disease free survival
29980240 L1CAM DFS p=0.006 High level of L1CAM were associated with lower DFS in patients with stage of tumor <1B
29980240 miR-34a DFS p=0.0003 The correlation of these data with DFS identified a subgroup of patients with mRNA L/L1CAM H protein that showed lower DFS
29907137 GLP-1R PFS p=0.0110 High GLP-1R expression was significantly correlated with longer PFS.
29895385 signal intensity (SI) DFS p=0.014 Endometrial tumours showing a SI of >209 on delayed T1WI sequences had longer recurrence-free survival than those with tumours showing a SI ≤209
29653556 DFF40 OS HR: 2.757; CI: 1.644-4.624 p<0.001 Univariate analysis revealed that decreased DFF40 increased the negative HRs for OS
34339705 SMOC-2 DFS p<0.001 SMOC-2 high expression was positively correlated with disease-free survival
29653556 BCL2 OS HR: 6.277; CI: 3.522-11.189 p<0.001 Univariate analysis revealed that decreased BCL2 expression increased the negative HRs for OS
29653556 DFF40 DFS HR: and DFS (HR: 2.937; CI: 1.680-5.134; p<0.001 Univariate analysis revealed that decreased DFF40 increased the negative HRs for DFS
29653556 BCL2 DFS HR: 6.979; CI: 3.654-13.331; p<0.001 Univariate analysis revealed that decreased BCL2 expression increased the negative HRs for DFS
29626374 CC3 DFS p=.002 Patients with non-endometrioid tumours had significantly shorter DFS
29626374 CC3 OS p=.002 Low CC3 expression (CC3Low ) was significantly associated with shorter OS
29626374 CC3 DFS p=.002 When endometrioid and non-endometrioid tumours were assessed separately, CC3Low was significantly associated with shorter DFS in patients with non-endometrioid tumours.
29626374 CC3 OS p=.001 When endometrioid and non-endometrioid tumours were assessed separately, CC3Low was significantly associated with shorter OS in patients with non-endometrioid tumours.
29572029 PD-L1/CD8 ratio PFS log-rankp<0.0001 Classification of endometrial cancer into four groups based on CT-CD8 and CT-PD-1 revealed adverse prognostic significance of the CT-CD8Low + CT-PD-1Low group compared with all the other group combinations
29572029 PD-L1/CD8 ratio OS log-rankp<0.0001 Classification of endometrial cancer into four groups based on CT-CD8 and CT-PD-1 revealed adverse prognostic significance of the CT-CD8Low + CT-PD-1Low group compared with all the other group combinations
29572029 PD-L1/CD8 ratio PFS HR 4.653 (1.675–12.927) the CT-PD-L1/CT-CD8 ratio was an independent poor prognostic factor for PFS in all patients and in the MSS subgroup
34339705 SOX17 OS p=0.001 SOX17 negative expression was positively correlated with overall survival
29572029 PD-1 OS [HR 0.243 (0.054–1.088) log-rankpraw=0.0447,log-rankpFDR= 0.1043] High PD-1 expression center of tumor (CT) was associated with favorable OS
29572029 PD-1 OS HR 0.125 (0.01–1.074) log-rankpraw=0.0243,log-rankpFDR=0.0851 High PD-1 expression invasive margin (IM) was associated with favorable OS
29572029 PD-1 OS HR 0.251 (0.056–1.122) log-rank praw=0.0504 high CT-PD-1/CT-CD8 ratio was associated with favorable OS
29572029 PD-1 PFS HR 0.436 (0.167–1.135) log-rankpraw= 0.0799 high CT-PD-1/CT-CD8 ratio was associated with favorable OS
29572029 PD-L1 PFS HR 2.879 (1.147–7.227) log-rankpraw=0.0183,log-rank pFDR=0.0427 High IC-PD-L1 expression in center of tumor was associated with an adverse PFS
29572029 PD-L1 PFS HR 4.356 (1.208–15.711) log-rankpraw =0.0139,log-rankpFDR=0.0427 High PD-L1 expression invasive margin (IM) was associated with an adverse PFS
29572029 CT-CD8 OS HR 0.107 (0.024–0.482) log-rankpraw=0.0004,log-rankpFDR=0.0028 High CT-CD8 density was associated with favorable OS
29572029 CT-PD-L1/ CT-CD8 PFS HR 5.690 (2.343–13.816 log-rankprawb0.0001,log-rankpFDR= 0.0001] CT-PD-L1/ CT-CD8 was associated with adverse PFS
29572029 CT-PD-L1/ CT-CD8 PFS HR 4.653 (1.675–12.927) CT-PD-L1/ CT-CD8 was an independent poor prognostic factor in all patients
29526558 TRIM44 OS p<0.05 TRIM44 overexpression was associated with independent prognostic factor for overall survival
34339705 SOX17 DFS p=0.001 SOX17 negative expression was positively correlated with disease-free survival
29526558 TRIM44 PFS p<0.05 TRIM44 overexpression was associated with independent prognostic factor for PFS
29516012 visfatin OS p=0.0001 High baseline visfatin levels was correlated with shorter overall survival
29516012 UCHL1 DFS p=0.002 High UCHL1 mRNA was correlated with reduced DFS
29516012 UCHL1 OS p=0.015 High UCHL1 mRNA was correlated with reduced OS
29516012 visfatin OS HR = 0.97 p=0.03 In the univariate OS model, both median visfatin level and cut-off baseline visfatin level (20.7 ng/ml) were significant variables. A correlation was demonstrated between median visfatin levels and overall survival of patients
29463191 HE4 DFS 2.96 (95% confidence interval: 1.18-7.99) Elevated serum HE4 was an independent prognostic factor for reduced disease-free survival
29463191 HE4 OS 3.27 (95% confidence interval: 1.18-9.02) Elevated serum HE4 was an independent prognostic factor for reduced overall survival
29169184 HER2 DSS p<0.001 The 5-year DSS for patients with primary tumours with low HER2 expression (0–2+) was 87, vs 77% for patients with HER2-high expressing tumours (3+)
29169184 HER2 survival p<0.001 In univariate survival analysis, patients with low HER2 (SI 0–6) tumours had a 5-year DSS of 87, vs 61% for patients with high HER2 (SI 9) tumours
29169184 HER2 survival p=0.003 High HER2 SI (SI 9) associated with poor outcome compared with SI 0–6
34331128 microRNA-21 PFS p=0.004 In all endometrial cancer cases, PFS curves showed statistically signifcant diferences between patients with high miR21 expression and those with low miR-21 expression in cancer cells
29169184 HER2 survival HR 1.61 (95% CI: 0.91–2.85 p=0.1 In multivariate survival analysis corrected for age, stage and grade, High HER2 (SI 9) independently associated with survival, although not significant
29096882 Asparaginase-like protein 1 survival p<0.001 Low expression of ASRGL1 protein and ASRGL1 mRNA predicted poor disease specific survival
29096882 Asparaginase-like protein 1 survival Hazard ratio (HR): 1.53, 95% confidence interval (CI): 1.04-2.26 p=0.031 In multivariate survival analyses ASRGL1 had independent prognostic value both in the whole patient cohort
29096882 Asparaginase-like protein 1 survival HR: 2.64, CI: 1.47-4.74 p=0.001 In multivariate survival analyses ASRGL1 had independent prognostic value within the endometrioid subgroup
29096882 Asparaginase-like protein 1 DSS p<0.001 patients with low ASRGL1 mRNA expression had significantly worse 5 year disease specific survival (DSS) compared to patients with high ASRGL1 mRNA expression (5 year DSS of 0.60 and 0.87, respectively
28980703 IRAK1 survival p<0.05 IRAK1 was upregulated at RNA level was correlated with poor patients’ survival
28980703 IRAK1 survival p<0.01 IRAK1 expression was correlated with poor patients’ survival
28965628 cyclin D1 survival p=0.011 Significant different survival distributions were observed and poor survival behavior was correlated with negative cyclin D1 immunohistochemical staining. In conclusion, greater frequency of cyclin D1 expression was revealed in normal endometrial tissues in comparison with carcinomas.
28836043 NTSR1 OS p=0.0012 NTSR1 messenger RNA (mRNA) was negatively correlated with overall survival (OS)
28836043 NTSR1 PFS p=0.0116 NTSR1 messenger RNA (mRNA) was negatively correlated with progression-free survival (PFS)
34331128 microRNA-21 PFS hazard ratio=2.460 p=0.041 Cox’s univariate and multivariate analyses of PFS in endometrioid carcinoma revealed that high miR-21 expression (cancer cells) were signifcant indicators of a poor prognosis (in multivariate analysis, hazard
28836043 NTSR1 OS log-rank:p<0.0001 NTSR1 mRNA level continued to be negatively correlated with OS
28836043 NTSR1 PFS p=0.002 NTSR1 mRNA level continued to be negatively correlated with PFS
28836043 NTSR1 OS p<0.001 High immunohistochemical expression of cytoplasmic NTSR1 was correlated with a shorter OS
28836043 NTSR1 PFS p=0.001 High immunohistochemical expression of cytoplasmic NTSR1 was significantly correlated with a shorter PFS
28836043 NTSR1 DFS p=0.004 High immunohistochemical expression of cytoplasmic NTSR1 was an independent prognostic factor for reduced disease-free survival
28794448 CD133 OS 95% CI, 154-168 VS 95% CI, 123-160 p=0.012 The mean OS for CD133+ tumour patients was 161 months (95% CI, 154–168) as compared with 146 months (95% CI, 123–160) for those with CD133- tumors
28794448 CD133 PFS 95% CI, 149–168 VS 95% CI, 132-161) p=0.014 The mean PFS for CD133+ tumour was 159 months (95% CI, 149–168) as compared with 147 months (95% CI, 132-161) in those with a CD133-tumour
28794448 CD133 OS/PFS HR 4.731 (95% CI, 1.251–17.89) p=0.022 C133+ tumours predicted favorable OS and PFS of EEC patients, with a Hazard Ratio 4.731
28751757 L1CAM survival p<0.001 Expression of L1CAM were associated with features of aggressive disease and poor outcome
28751757 L1CAM survival p<0.001 Hysterectomy samples L1CAM were associated with poor outcome
34306255 GABPA OS 0.487 (0.246-0.966) p=0.040 In univariate analysis, the low expression of GABPA was corresponded to poor prognosis of OS
28751757 L1CAM DSS p<0.001 High expression of L1CAM in curettage specimen predicted poor disease-specific survival in the whole patient population
28751757 L1CAM survival HR 2.7 (95% CI 1.8–4.3 p<0.001 Expression of L1CAM also showed independent prognostic impact in Cox survival analysis after correction for age, FIGO stage, histologic subtype and grade assessed in the hysterectomy specimens
28668893 GalNAc-T6 OS p=0.003 None
28668893 GalNAc-T6 survival p=0.013 GalNAc-T6 expression was an independent prognostic factor
28668893 GalNAc-T6 OS p<0.05 Univariate survival analysis showed that positive GalNAc-T6 expression had better overall survival
28668893 GalNAc-T6 survival p=0.013 The multivariate analysis using the Cox proportional hazards model showed GalNAc-T6 expression to be an independent prognostic factor among the studied variables
28643014 NAV2 OS p=0.037 NAV2 expression was associated with shorter overall survival in patients with uterine leiomyosarcoma in univariate analysis
28643014 CCND2 survival p=0.012 nuclear CCND2 expression in LG-ESS was significantly related to longer survival in univariate analysis
28643014 CCND2 survival p=0.023 Nuclear CCND2 expression was an independent prognosticator in Cox multivariate analysis
28624692 YKL-40 disease progression Ch2 = 4.39 p<0.036 In patients who had disease progression, the percentage of elevated concentrations of YKL-40 (53%) was higher than in patients in remission. The Chisquare test demonstrated that these differences were statistically significant:
34306255 GABPA OS 0.491 (0.246-0.977) p=0.043 The multivariate Cox proportional hazard model showed that lower expression of GABPA was an independent poor prognostic factor for OS
28624692 CA 125 death status p<0.038 The Mann-Whitney test showed that in patients who died during the follow-up period, the CA 125 levels were significantly higher compared to the concentrations in patients who were alive.
28453461 SerpinE2 OS p=0.045 When comparing the 5 year overall survival rate of the two groups, there was a significant difference between the high and the low SerpinE2 expression group
28401338 HE4 surviva HR 5.12 per 10-fold increase in HE4, 95% CI 1.54-17.1 p=0.008 Serum HE4 concentration is significantly associated with independent prognostic factor for recurrence-free survival
28401338 HE4 OS HR 7.48 per 10-fold increase in HE4, 95% CI 1.76-31.7 p=0.006 Serum HE4 concentration is significantly associated with overall survival
28277313 androgen receptor (AR) DFS p=0.008 AR expression was correlated with increased disease-free survival
28187032 Tyrosine Phosphatase SHP-1 survival HR=0.32 (0.11 to 0.94)P=0.039 p=0.039 From both univariate and multivariate analysis in the Ec group, expression of SHP-1 remained a positive prognostic factor
27926484 lncRNA H19 OS HR=2.710 p<0.05 Kaplan-Meier analysis revealed that patients with uterine corpus cancer and higher H19 expression had a shorter OS
27926484 lncRNA H19 RFS HR=2.261 p<0.05 Females with cervical cancer and increased H19 expression had a shorter RFS
27926484 lncRNA H19 survival HR=4.099 p<0.05 High H19 expression was poorer prognosis in cervical cancer patients
27923582 HSD17B2 survival p=0.005 Patients having low HSD17B2 levels had a statistically non-significant poorer prognosis compared with the remaining patients
34306255 GABPA DFS HR: 0.619, CI: 0.397-0.966 p=0.045 The multivariate Cox proportional hazard model showed that lower expression of GABPA was an independent poor prognostic factor for DFS
27923582 HSD17B1 survival p=0.007 Patients with high levels of HSD17B1 had a significantly poorer prognosis than the remaining patients
27923582 HSD17B1 survival p=0.013 patients with a tumour expressing high levels of HSD17B1 mRNA and low levels of HSD17B2 mRNA had the worst prognosis
27873306 ALCAM survival HR 6.027; 95% CI 1.41-25.74 In multivariate analysis, ALCAM-positivity was an independent prognostic factor in early stage disease
27873306 ALCAM DFS HR 4.237; 95% CI 1.01-17.76 Recurrence-free survival was poorer in patients with ALCAM-positive compared to ALCAM-negative tumours
27648714 L1CAM DFS p<0.0001 L1CAM predicted poor disease-specific survival in endometrioid (P < 0.0001) but not in non-endometrioid carcinomas
27634881 HIF-1α survival p=0.005 In the tumor stroma was significantly associated with reduced survival
27634881 HIF-1α survival hazard ratio (HR) of 1.7 p=0.04 High stromal HIF-1α expression were an independent unfavorable prognostic factor
27634881 HIF-1α survival p=0.01 High stromal HIF-1α expression were associated with decreased survival
27549092 CA-125 DFS p=0.01 Increased pre-operative serum CA-125 levels were significantly associated with lower DFS
27549092 CA-125 OS p=0.006 Increased pre-operative serum CA-125 levels were significantly associated with lower OS
34731191 TET1 PFS p=0.034 Patients with EC with a lower score (≤20) had worse PFS than those with a higher score (>20)
34306255 GABPA OS HR: 0.488, CI: 0.258-0.922 p=0.036 Patients with low expression levels of GABPA protein had relatively poorer OS than patients with high expression levels of GABPA
27540975 UCA1 OS p=0.023 The 5-year overall survival rate in the high expression group VS in the low expression group
27226215 PAX1 OS hazard ratio of 0.22 for death (95% confidence interval, 0.05-0.96) A higher PAX1 score in EC cases was correlated with good overall survival, with a hazard ratio of 0.22 for death
27079211 BIRC5 PFS HR=1.97, 95% CI=1.29-4.5, p=0.045 High expression of BIRC5 was associated with poor progression free survival (P=0.006), and shown to be an independent prognostic factor
27038842 CD103 survival p=0.035 The presence of a high CD103+ cell infiltration was associated with an improved prognosis in patients with endometrial adenocarcinoma
27003026 SLUG RFS hazard ratio 5.938, 95% confidence interval 1.251-28.18 p= 0.025 High expression of SLUG were independent prognostic factors of worse RFS
27003026 SLUG OS p=0.00963 Overall survival was worse in patients with high SLUG expression in those who underwent adjuvant therapy
27003026 SLUG stages III/IV/RFS p=0.0146 High SLUG expression was associated with worse recurrence-free survival (RFS) in the patients in patients at stages III/IV
27003026 SLUG RFS p=0.00264 High SLUG expression was associated with worse recurrence-free survival (RFS) in the patients at all stages
27003026 SLUG RFS/stage p=0.00264 High SLUG expression was associated with worse recurrence-free survival (RFS) in the patients at all stages
27003026 SLUG RFS/adjuvant therapy p=0.000743 High SLUG expression was associated with worse recurrence-free survival (RFS) in the patients who underwent adjuvant therapy
34306255 GABPA DFS HR: 0.584, CI: 0.375-0.910 p=0.018 Patients with low expression levels of GABPA protein had relatively poorer DFS than patients with high expression levels of GABPA
26991548 CD169(+) macrophages in RLN survival Density of CD169+ macrophages in RLN associated with an improved prognosis
26957478 Estrogen receptor-alpha DFS 80.5% (95% CI: 0.65–0.90) VS 85.1% (95% CI: 0.79–0.90) logrank-testp-value=0.268 None
26957478 Estrogen receptor-alpha OS 82.1% (95% CI: 66.2–91.0) and 88.4% (95% CI: 82.2–92.5) p-value=0.114 None
26842712 NUCB2 survival p=0.0004 NUCB2 immunoreactivity was significantly associated with worse prognosis
26647729 CCNE1 PFS p=0.0081 CCNE1 amplification were correlated with shorter progression-free
26647729 CCNE1 OS p=0.0073 CCNE1 amplification were correlated with shorte roverall surviva
26647729 CCNE1 OS Multivariate analysis showed that CCNE1 amplification was an independent prognostic factor for overall survival but not for progression-free survival
26588239 TOP2A OS p=0.020 Patients with TOP2A-positive tumors had significantly lower overall survival than did patients with TOP2A-negative tumors
26588239 HER2 DFS p=0.049 Disease-free survival for patients with HER2-positive tumors was significantly lower than disease-free survival for patients with HER2-negative tumors
26554657 CDK4/6 PFS p=0.024 Patients with high CDK4/6SA (>3.0) showed significantly shorter progression-free survival (PFS) than those with low CDK4/6SA (<3.0).
34306255 GABPA OS HR: 0.488, CI: 0.258-0.922 p=0.036 low expression levels of GABPA protein vs high expression levels of GABPA
26554657 CDK4/6 PFS p=0.015 The combination of high CDK4/6SA and high Ki-67 expression (>15%) was robustly associated with shorter PFS , and this combination was an independent poor prognostic factor in the low-risk group.
26539494 HE4 mortality in endometrial cancer p<0.05 Mortality in endometrial cancer patients with high HE4 expression was significantly higher than that in patients with low HE4 expression
26539494 HE4 survival p=0.027 Kaplan-Meier survival analysis showed that endometrial cancer patients with strongly positive expression of HE4 had significantly higher mortality than those without strongly positive expression of HE4
26362938 ANXA2 survival hazard ratio [HR] = 8.004 p<0.05 ANXA2 was an independent risk factor for the prognosis of endometrial carcinoma
26260911 Metabolic syndrome OS p=0.001 The OS rate of the patients with endometrial adenocarcinoma with MS was significantly worse than that of the patients without MS for all 385 patients
26260911 Metabolic syndrome survival p=0.049 Metabolic syndrome was independent prognostic factors for endometrial adenocarcinoma
26222488 COX-2 survival p=0.06 There was a clear trend for more favorable 5-year survival in patients with a high staining score than in those with a low score, and the difference was of borderline significance
26191146 Musashi-1 protein survival HR=2.073 p=0.001 Higher protein expression level of Musashi-1 are associated with poor survival rate than those with negative or low level of expression
26191146 Musashi-1 protein OS p =0.0006 Patients with negative or weak staining of Musashi-1 had markedly longer OS than with moderate or high staining group
26166558 LSD1 OS of patients with EEA p=0.027 LSD1 expression status was an independent prognostic factor for OS of patients with EEA.
34306255 GABPA DFS HR: 0.584, CI: 0.375-0.910 p=0.018 In univariate analysis, the low expression of GABPA protein was corresponded to poor prognosis of DFS
26166558 LSD1 DFS of patients with EEA p=0.016 LSD1 expression status was an independent prognostic factor for DFS of patients with EEA.
26111272 COX-2 survival p=0.038 The prognosis was significantly poorer in the patients with MSI-positive tumors with high COX-2 expression than in those with MSI-positive tumors showing low COX-2 expression.
26111272 COX-2 survival p=0.003 Comparison of cancer-specific survival rate in relation to COX-2 expression level in MSI-positive (A)
25964114 CA125 survival χ2=186.60 p<0.01 Cox regression model simultaneously, CA125, were identified as independent prognostic factors
25951350 Enolase-1 survival p=0.036 Patients with high expression had worse prognoses than those with low expression of ENO1
25934333 ANCCA OS p=0.001 ANCCA expression exhibited significantly poorer overall survival (OS) than patients with low ANCCA expression
25934333 ANCCA DFS p=0.002 ANCCA expression exhibited significantly disease-free survival (DFS) than patients with low ANCCA expression
25934333 ANCCA OS hazard ratio (HR) = 4.954, 95 % confidence interval (CI) = 1.537-15.966 p=0.007 High ANCCA expression were an independent prognostic factor for OS
25934333 ANCCA DFS HR = 4.237, 95 % CI = 1.295-13.859 p=0.017 High ANCCA expression were an independent prognostic factor for DFS
25874492 Sam68 OS p<0.001 Univariate analysis demonstrated that overexpression of Sam68 correlated with shorter overall survival
34257552 ARID1A RFS 8.7 (95% CI 1.09–69.6) p=0.04 Multivariate analysis showed significantly longer RFS among patients with ARID1A loss
25874492 Sam68 OS p=0.048 Multivariate analysis demonstrated that overexpression of Sam68 correlated with shorter overall survival
25874492 Sam68 OS Kaplan-Meier analysis demonstrated that overexpression of Sam68 correlated with shorter overall survival
25858696 ASRGL1 DFS/EEA 3.55 (95% CI=1.10-11.43) p=0.003 Reduced expression of ASRGL1, defined as <75% positively stained tumor cells, was significantly associated with poor prognosis and reduced disease-specific survival in endometrioid endometrial adenocarcinoma (EEA) in one cohort
25858696 ASRGL1 DFS/EEA 3.23 (95% CI=1.53-6.81) p=0.002 Reduced expression of ASRGL1, defined as <75% positively stained tumor cells, was significantly associated with poor prognosis and reduced disease-specific survival in endometrioid endometrial adenocarcinoma (EEA) in one cohort
25731151 Ca125 OS p=0.021 Raised Ca125 correlates to worse overall disease-specific survival (66.1 vs 87.8 months)
25731151 Tag72 DFS p=0.021 Tag72 correlates to higher recurrence rate
25731151 Tag72 DFS p=0.021 Tag72 correlates to shorter disease-free survival
25731151 Ca125+Tag72 DFS p=0.018 Both Ca125 and Tag72 are abnormal DFS is worse
25731151 Ca125+Tag72 DOS p=0.021 Both Ca125 and Tag72 are abnormal DOS is worse
25505230 POLE proofreading mutations death status Women with POLE-mutant ECs had EC deaths
34257552 ARID1A RFS p=0.040 Kaplan-Meier analysis showed retained ARID1A expression predicting lower RFS in the whole cohort
25505230 POLE proofreading mutations RFS multivariable-adjusted HR = 0.11, 95% CI = 0.001 to 0.84, p=.03 Of 109 grade 3 tumors, 0 of 15 POLE-mutant ECs recurred, compared with 29 of 94 (30.9%) POLE wild-type cancers; reflected in statistically significantly greater RFS
25505230 POLE proofreading mutations RFS multivariable-adjusted, pooled HR= 0.33 95% CI = 0.12 to 0.91 p=.03 There were no EC-related events in any of 33 POLE-mutant ECs, resulting in a multivariable-adjusted, pooled HR of 0.33 for RFS
25355598 HABP1 OS p=0.015 high HABP1 expression had a poorer overall survival (OS) than patients with low HABP1 expression
25355598 HABP1 DFS p=0.012 Patients with high HABP1 expression had a poorer disease-free survival (DFS) than patients with low HABP1 expression
25355598 HABP1 OS p=0.025 HABP1 expression status was an independent prognostic factor of OS
25355598 HABP1 DFS p=0.022 HABP1 expression status was an independent prognostic factor of DFS
25347096 SATB1 OS p<0.001 Positive SATB1 expression had worse overall survival than the patients with negative SATB1 expression
25347096 SATB1 DFS p<0.001 Positive SATB1 expression had worse disease-free survival rates than the patients with negative SATB1 expression
25347096 SATB1 OS hazards ratio, 2.928; 95% confidence interval, 1.072-7.994 p=0.036 Multivariate Cox analysis indicated that SATB1 was an independent parameter for overall survival
25347096 SATB1 DFS (hazards ratio, 2.825; 95% confidence interval, 1.111-7.181; p=0.029 Multivariate Cox analysis indicated that SATB1 was an independent parameter for disease-free survival
34109467 HE4 death status p=0.002 Serum HE4 levels was significantly associated with death status
25315186 cyclin B CSS Survival analyses showed that cyclin B expression affects cancer-specific survival in univariate analysis
25310854 MSI PFS p=0.013 Five-year PFS was 92% in MMR-deficient patients, and 78% in MMR-retained patients
25310854 MSI OS p=0.009 5-year OS was 94% in MMR-deficient patients, and 78% in MMR-retained patients
25310854 MSI survival hazard ratio, 0.24; 95% confidence interval, 0.08 to 0.70 p=0.008 In multivariate analyses, MMR-deficient status was identified as an independent better prognostic factor for OS in endometrial cancers
25275055 Intraepithelial CD3(+) TIL counts early tumors. Intraepithelial CD3(+) TIL counts are an independent predictor of survival in patients with early tumors.
25275055 intraepithelial CD8+ TIL count survival HR=0.28, 95% CI=0.10-0.76, p=0.01 In multivariate analysis ,intraepithelial CD8+ TIL counts below 9 per mm2 were associated with improved prognosis
25275055 Intraepithelial CD3(+) TIL counts survival HR=3.79, 95% CI=1.34-10.71 p=0.01 In patients with early-stage, high-risk tumors, CD3+ TIL counts below 17 per mm2 were associated with inferior prognosis in multivariate analysis
25254562 CRHR1 survival p=0.009 CRHR1 status was significantly associated with an increased incidence of worse prognosis
25254562 CRHR1 survival p=0.009 CRHR1 status were significant prognostic factors
25254562 PR DFS p=0.001 The results of univariate analysis of disease-free survival by Cox model indicated PR status as significant prognostic factors for disease-free survival
33858677 p53/L1CAM/ER/PR RFS/DSS p<0.001 Patients with LNM (N1) and p53-abn or L1CAM+ had significantly decreased RFS/DSS compared with, patients having LNM (N1) and normal IHC expression (p53-wt or L1CAM-), and patients without LNM (N0) and normal/abnormal IHC expression.
25254562 CRHR1 DFS p=0.023 The results of univariate analysis of disease-free survival by Cox model indicated CRHR1 status as significant prognostic factors for disease-free survival
25254562 PR survival p =0.010 Multivariate analysis demonstrated PR as independent prognostic factors with relative risks greater than 1.0.
25254562 CRHR1 survival p=0.027 Multivariate analysis demonstrated CRHR1 as independent prognostic factors with relative risks greater than 1.0.
25254562 PR survival p=0.015 In the univariate analysis for overall survival, PR status were significant prognostic factors
25254562 CRHR1 survival p=0.009 In the univariate analysis for overall survival, CRHR1 status were significant prognostic factors
25033726 WT-1 DFS p=.031 WT-1 had a shorter DFS compared with those with no WT-1 expression
25022554 HER-2/neu survival Multivariate Cox regression analysis showed that HER-2/neu expression were independent prognostic factors for OS, CRS and DFS
24972085 Yes-associated protein (YAP) OS p=0.015 Increased nuclear YAP expression was significantly associated with overall survival in estrogen mediated EMCA, called type 1 cancer
24972085 Yes-associated protein (YAP) OS p<0.021 In multivariate analysis, nuclear YAP expression was confirmed as an independent prognostic factor for overall survival in type 1 EMCA.
24972085 Yes-associated protein (YAP) OS p = 0.015 Kaplan-Meier survival estimates showed that increased nuclear immunoreactivity of YAP was significantly associated with worse overall survival in type 1 cancer
33832498 mesothelin PFS [HR]=2.14 p<0.01 In the multivariate analysis, mesothelin expression were poor prognostic factors for PFS
24966915 Rictor OS p<0.05 The OS of Rictor-negative group was distinctly better than that of the Rictor-positive one for all 249 samples separated according to pathological type, grade, vascular invasion and lymphatic metastasis
24966915 Rictor survival 8.612(1.034-71.702) p=0.046 Multivariate Cox proportional hazards regression analyses showed that Rictor were independent prognostic factors for EC in Test cohor .
24966915 Rictor survival 8.736(1.050-72.707) p=0.045 Multivariate Cox proportional hazards regression analyses showed Rictor were independent prognostic factors for EC in validation cohort.
24930886 KPNA2 OS hazard ratio 1.7, 95% CI 1.13-2.5 p=0.01 Increased nuclear KPNA2 immunoreactivity was identified as a novel predictor of overall survival, independent of well-established prognostic factors in Cox regression analyses
24853175 HSF1 survival p=0.03 The significant prognostic impact of HSF1 level was also reflected when exploring mRNA level with worst outcome for patients with expression levels above the upper tertile
24853175 HSF1 survival p<0.02 High expression of HSF1 protein in endometrial carcinoma is significantly associated with poor survival
24853175 HSF1 survival p=0.08 HSF1 showed a tendency, although not statistically significant, as an independent marker of prognosis
24853175 HSF1 survival/ERα hazard ratio (HR): 6.2; 95% confidence interval (CI) 1.5–26.4; p=0.014 we found HSF1 to be an independent prognostic marker only in the group of ERα-positive patients
24853175 HSF1 survival HR: 2.3; 95% CI 1.0–5.3 p=0.04 we found the HSF1-CaSig signature to independently predict poor survival
24849812 FOXA1 DSS p = 0.004 Low FOXA1 protein expression was significantly associated with reduced disease specific survival
33832498 mesothelin PFS HR=2.19 p<0.01 In the multivariate analysis, co-expression were poor prognostic factors for PFS
24844595 POLE exonuclease domain mutations PFS p=0.025 The presence of POLE exonuclease domain mutation was associated with significantly better progression-free survival in univariate
24844595 POLE exonuclease domain mutations survival p=0.010 Multivariateanalyses, such that none of the patients with POLE mutated tumors experienced disease progression
24756855 S100A4 Disease progression p=0.000 Disease progression was observed in 37.1% (13/35) of the patients with expression of S100A4 and in 15.0% (15/100) of those with no S100A4 expression. This difference reached a statistical significance
24756855 S100A4 death status p=0.000 The proportion of disease-related deaths was 22.9% (8/35) in the patients with S100A4 expression and 3.0% (3/100) in those with no S100A4 expression
24692842 HDGF OS p=0.001 Patients with high expression of HDGF had poorer overall survival rates than those with low expression of HDGF
24670463 MMP2 survival p=0.041 MMP2 over-expression was negatively correlated with prognosis
24659664 CA 125 DFS and OS p=0.043 Preoperative serum CA 125 levels were independent prognostic factors for DFS and OS
24590269 TNFAIP8 DFS p=0.022 Multivariate Cox regression analysis revealed that TNFAIP8 was independent factors of DFS in patients with EC.
24587245 Stathmin DFS p = 0.03 Within the subgroup of patients with metastatic disease treated with paclitaxel containing chemotherapy, disease specific survival was significantly poorer in those patients with high compared to normal stathmin
24587245 Stathmin DFS n = 38,HR 2.3, CI 1.1–5.2 Stathmin protein level remained an independent predictor of disease specific survival in the subgroup of patients that received paclitaxel containing chemotherapy
34731191 TET1 HR 0.34 (95% confidence interval [CI]: 0.14–0.85; p<0.05 Univariate survival analysis revealed that higher TET1 expression level (>20) resulted in a HR of death = 0.34 (95% confidence interval [CI]: 0.14–0.85; p < 0.05),
33832498 mesothelin OS HR = 2.18 p<0.01 In the multivariate analysis, mesothelin expression were poor prognostic factors for OS
24587245 Stathmin DFS n = 43,HR 1.1, CI 0.4–2.7 Stathmin protein level ,djusted for FIGO stage and histological subtype, were not an independent predictor of disease specific survival in the subgroup receiving other therapies
24377825 GdA survival p=0.002 Cox-regression analysis proofed GdA to be an independent prognostic marker for patient survival
24377825 Gd survival p=0.039 Gd positive cases have a favourable prognosis
24377825 GdA survival p=0.003 GdA positive patients have a poor outcome
24377825 GdA survival 95% CI 1.362-3.943 p=0.002 Cox-regression analysis proofed GdA to be an independent prognostic marker for patient survival
24335662 estrogen receptor-α survival//USC p<0.05 The univariate analyses showed an expression of ER-α to be a significant prognostic indicator in patients with USC
24333732 CD117 survival p<0.05 The Cox-regression hazard model identified high CD117 expression to be an independent prognostic factor for survival
24333732 CD117 survival p<0.001 CD117 expression was significantly associated with poor overall survival and relapse-free survival
24333732 CD117 survival p<0.05 The Cox-regression hazard model identified high CD117 expression to be an independent prognostic factor for survival
24222154 E-Cadherin survival p=0.04 In a restricted multivariate model, only tumor stage and E-Cadherin expression retained their independent prognostic power, both for the whole group of tumors
33832498 mesothelin OS HR = 2.22 p<0.01 In the multivariate analysis, co-expression were poor prognostic factors for OS
24222154 E-Cadherin OS p=0.012 E-Cadherin overexpression was associated with a significantly better overall survival in the whole group of patients with endometrial carcinoma
24211402 Serum HE4 RFS HR=2.40, 95% CI 1.19-4.83 p=0.014 Cox multivariate analysis demonstrated that elevated HE4 was an independent predictor of recurrence-free survival
24211402 Serum HE4 RFS/endometrioid subtype HR=2.86, 95% CI 1.25-6.51 p=0.012 Cox multivariate analysis demonstrated that elevated HE4 was an independent predictor of recurrence-free survival in the endometrioid subtype
24146786 MAI DFS p=0.001 The MAI was prognostic
24146786 PPH3 survival p=0.002 PPH3 was prognostic
24146786 Ki-67 survival p=0.03 Ki-67 was prognostic
24011381 albumin DFS p=0.02 In a multivariable analysis pre-treatment serum albumin levels was independently associated with disease-free
24011381 albumin RFS p=0.001 In a multivariable analysis pre-treatment serum albumin levels was independently associated with progression-free survival
23947899 CyclinD1 discrimination HR2.765, 95% CI: 1.201–6.363, p<0.05 CyclinD1 staining were significantly associated with prognosis
23932335 double negative hormone receptor DFS (hazard ratio (HR) 2.3, 95% CI 1.4-3.9) ER/PR loss predicted poor disease-specific survival adjusted for age, FIGO stage, histologic type, grade and myometrial infiltration
33787629 L1CAM OS HR = 2.87, 95% CI1.81-4.55 p<.001 Results showed L1CAM overexpression to be significantly associated with decreased overall survival
23932335 double negative hormone receptor survival Double negative ER/PR showed independent prognostic impact in Cox survival analysis, adjusted for age, FIGO stage, myometrial infiltration, histologic subtype and grade assessed in hysterectomy specimens
23896713 Ki-67 CSS/PFS High proliferative index of Ki-67 were significant prognostic factors for both progression-free survival and CSS in a univariate analysis
23782748 combined OATP1B3/CTR1 DFS p=0.047 In univariate analysis, high expression levels of OATP1B3 was significantly associated with longer disease-free survival (DFS) and longer overall survival (OS)
23782748 combined OATP1B3/CTR1 DFS p=0.009 In univariate analysis, high expression levels of CTR1 was significantly associated with longer disease-free survival (DFS) and longer overall survival (OS)
23782748 combined OATP1B3/CTR1 DFS p=0.058 The patients with tumors showing high expression levels of at least one of OATP1B3 and CTR1 had potentially longer DFS
23782748 combined OATP1B3/CTR1 DFS p=0.013 Combined OATP1B3/CTR1 expression was the sole independent prognostic factor for longer OS in the multivariate analysis
23782748 combined OATP1B3/CTR1 OS p=0.003 The patients with tumors showing high expression levels of at least one of OATP1B3 and CTR1 had potentially significantly longer OS
23781004 L1CAM death status HR = 15.01; 95% CI = 9.28 to 24.26) Multivariable analyses revealed an increase in the likelihood of death
23781004 L1CAM death A classification and regression decision tree (CRT)identified L1CAM as the best variable for predicting death
23777659 progesterone receptor DFS p=0.001 In univariate analysis negative PR expression was associated with a shorter disease-free survival
33787629 L1CAM DFS HR = 3.32,95% CI; 1.99-5.55 p<.001 Results showed L1CAM overexpression to be significantly associated with disease-free survival
23777659 progesterone receptor DFS p=0.019 In multivariate analysis only negative PR expression was significantly associated with a shorter disease-free survival
23617619 core 2 β1,6-N-acetylglucosaminyl transferase 1 (C2GnT1) survival p=0.017 Multivariable analysis also indicated that C2GnT1 overexpression was an independent prognostic factor
23524907 P53 PFS p=0.01 The median progression-free survival for the p53-wt group (88 mo) was significantly longer than the p53[+] group (56 mo)
23524907 P53 OS p=0.07 On univariate analyses, the median overall survival for the p53-wt patients (83 mo) was longer than the p53[+] patients (63 mo)
23438672 visfatin OS p=0.035 The overall survival rate of EC patients was significantly higher in the group with negative visfatin expression than with positive visfatin expression
23321718 Wnt7a OS p=0.034 Multivariate Cox regression analysis revealed that Wnt7a expression status was an independent prognostic factor for OS of patients with endometrial cancer.
23321718 Wnt7a DFS p=0.009 Multivariate Cox regression analysis revealed that Wnt7a expression status was an independent prognostic factor for DFS of patients with endometrial cancer.
23257935 ER-α36 DFS p<0.01 The disease-free survival rate of patients with ER-α36 expression was poorer than that of those who were negative for ER-α36 expression
23221606 p53 and ki67 DFS p=0.002 The 5-year DFS rates were 88%, 46%, and 0% for the p53(-)/ki67(-) group (n = 18), p53(-)/ki67(+) group (n = 17), and p53(+)/ki67(+) group (n = 4)
23221606 p53 and ki67 OS p<0.001 the 5-year OS rates were 100%, 71%, and 0%, for the p53(-)/ki67(-) group (n = 18), p53(-)/ki67(+) group (n = 17), and p53(+)/ki67(+) group (n = 4)
33754208 CHK1 death status HR 0.35, 95% CI 0.16–0.77 p=0.01 CHK1 expression > 379.2 (“high CHK1”) was associated with a decrease in the risk of death
23200913 GRP78 DFS hazard ratio 2.88, 95% CI 1.37-6.04, p=0.005 High visceral adipocyte GRP78 expression was significantly associated with decreased disease-free survival (DFS) in multivariate analyses
23179397 HE4 survival HE4 may be a new tool for preoperative evaluation and postoperative surveillance of endometrial cancer patients, with a HE4 at cutoff of 70 pmol/L yields the best sensitivity and specificity.
23114646 EMT survival p<0.01 EMT status, which was represented by both reduced E-cadherin and nuclear expression of Snail, was significantly associated with patient survival.
23114646 EMT OS p<0.01 A multivariate analysis showed that EMT-positive status was a significant predictor for both the progression-free survival and overall survival
23114646 EMT PFS 95% CI, 0.249–0.791 p=0.0059 EMT-positive status were found to be significant predictors of progression-free survival
23114646 EMT OS 95% CI, 0.197–0.678 p=0.0014 EMT-positive status were identified to be significant predictors of overall survival
23096757 HE4 survival In multivariate analysis, only high preoperative sHE4 concentrations, but not sCA125, were independent prognostic factors for shorter Overall Survival, Disease-Free Survival and Progression-Free Survival.
23051957 ERRγ and ERα status PFS p=0.03 Estrogen-related receptor γ immunoreactivity was associated with worse prognosis in PFS
23051957 ERRγ and ERα status OS p=0.048 Estrogen-related receptor γ immunoreactivity was associated with worse prognosis in OS
23051957 ERRγ and ERα status PFS p=0.01 ERRγ immunoreactivity was significantly associated with clinical outcomes in the patients with ERα-negative status in PFS
33660848 Carcinoembryonic antigen survival AUC = 0.709, 95% CI, 0.576-0.820, p=0.002 Receiver operating characteristic curve analysis revealed that CEA was good predictors of early-stage endometrial cancer
23051957 ERRγ and ERα status OS p=0.03 ERRγ immunoreactivity was significantly associated with clinical outcomes in the patients with ERα-negative status in OS
22945838 YKL-40 PFS /OS The PFS and OS for the YKL-40-positive patients were significantly shorter than those for the YKL-40-negative patients.
22886632 MMSET PFS /OS p<0.001 Patients with positive MMSET expression had significantly poorer overall survival and disease-free survival compared with patients with negative expression of MMSET
22886632 MMSET OS p=0.008 Multivariate Cox regression analysis revealed that positive MMSET expression was an independent prognostic factor for OS
22886632 MMSET DFS p=0.048 Multivariate Cox regression analysis revealed that positive MMSET expression was an independent prognostic factor for DFS
22824999 DNA ploidy PFS p<0.01 A DNA ploidy parameter, 5c exceeding rate, was found to be a prognostic marker for progression-free survival
22824999 DNA ploidy OS p=0.02 A DNA ploidy parameter, 5c exceeding rate, was found to be a prognostic marker for overall survival
22644303 pHH3 death p<0.0001 In univariate survival analysis, overexpression of pHH3 were associated with increased mortality
22644303 survivin death p<0.0001 In univariate survival analysis, overexpression of survivin were associated with increased mortality
22644303 pHH3 OS p=0.004 In the multivariable Cox regression analyses pHH3 could be identified as independent parameters for overall survival
33635467 BMP-10 TFS p=0.004 TFS rate in the low BMP-10 expression group were notably lower than those in the high BMP-10 expression group.
22644303 survivin OS p=0.023 In the multivariable Cox regression analyses survivin could be identified as independent parameters for overall survival
22640183 emmprin DFS p<0.001 The disease-free survival (DFS) of patients with high emmprin expression were significantly higher than those of patients with low emmprin expression
22640183 emmprin OS p<0.001 Overall survival (OS) rates of patients with high emmprin expression were significantly higher than those of patients with low emmprin expression
22617129 bFGF OS p=0.009 Tumour bFGF was significantly associated with poor OS
22617129 bFGF RFS p<0.001 Tumour bFGF was significantly associated with poor RFS
22617129 bFGF survival hazard ratio (HR): 0.14, 95% CI: 0.03, 0.60 In multivariable analyses, cases with HGF-positive, stromal bFGF-positive tumours had a lower risk of death compared with cases with HGF-positive, stromal bFGF-negative tumours
22525819 HE4 OS HR 2.407 p=0.017 In multivariate analysis HE4 was seen to have independent prognostic value in overall survival in contrast to CA125
22525819 HE4 OS p=0.001 In the subgroup endometrioid histological type (n=132) only HE4 was of prognostic value for overall survival in univariate
22525819 HE4 OS p=0.023 In the subgroup endometrioid histological type (n=132) only HE4 was of prognostic value for overall survival multivariate analysis
22315051 Gamma-glutamyltransferase (GGT) PFS p=0.03 Elevated and highly elevated serum GGT levels were independently associated with progression-free survival in univariate survival analyse
33635467 BMP-10 OS p=0.003 Os rate in the low BMP-10 expression group were notably lower than those in the high BMP-10 expression group.
22315051 Gamma-glutamyltransferase (GGT) PFS p=0.005 Elevated and highly elevated serum GGT levels were independently associated with progression-free survival in multivariable survival analyses
22270451 TIMP-2 survival The Cox regression analysis showed stage, grade and TIMP-2 to be significant predictors of survival.
22209294 phosphatidylinositol 3'-kinase pathway alteration survival p=.034 In univariate analysis, phosphatidylinositol 3'-kinase pathway activation (defined as PIK3CA mutation and/or phosphatase and tensin homolog loss) was associated with a favorable prognosis
22209294 phosphatidylinositol 3'-kinase pathway alteration survival/estrogen receptor-negative p=.048 In the estrogen receptor-negative subgroup, the phosphatidylinositol 3'-kinase pathway alteration was significantly related to prolonged patient survival
22198340 tumor budding (TB) OS TB has an independent impact on cumulative overall survival
22025313 CXCL12 OS p=0.006 Positive CXCL12 expression was associated with longer overall survival (OS)
22025313 CXCL12 RFS p=0.011 Positive CXCL12 expression was associated with longer recurrence-free survival (RFS)
22015044 Synuclein-γ (SNCG) protein DFS p=0.006 SNCG+ patients were more likely to have shorter DFS
22015044 Synuclein-γ (SNCG) protein survival p=0.006 SNCG+ patients were more likely to have a worse outcome
22015044 Synuclein-γ (SNCG) protein OS (p=0.1, HR=1.97, CI: 0.87–4.45) p=0.001 SNCG had a trend toward significance to predict OS with a 1.97-fold increased relative risk for SNCG+ patients in comparison to SNCG− patients
33635467 BMP-10 TFS HR: 13.712, 95% CI 1.823-103.158 p=0.011 Multivariate analysis showed that BMP-10 expression was an independent risk factor for the TFS of patients with EC
21849525 hPRL RFS p=0.041 Patients whose primary tumors did not express hGH mRNA had a mean 5-yr RFS rate of 66.7 , respectively, whereas patients with tumors expressing hGH mRNA exhibited a mean 5-yr RFS rate of 50%
21849525 hPRL RFS p=0.016 Patients whose primary tumors did not express hGH protein had a mean 5-yr RFS rate of 69.2%, whereas patients with tumors expressing protein both exhibited a mean 5-yr RFS rate of 50%
21849525 hGH OS p=0.024 Patients whose tumors were positive for expression of hGH mRNA exhibited a lower 5-yr OS rate than patients whose tumors were negative for hGH
21849525 hGH OS p=0.049 Patients whose tumors were positive for expression of hGH protein, respectively, exhibited a lower 5-yr OS rate than patients whose tumors were negative for hGH
21846440 CA 125 OS p=0.001 In women with serum CA 125 levels < 35 kU/L, five-year progression-free survival rates (88%) and overall survival rates (92%) were significantly better than in women with levels ≥ 35 kU/L
21764107 SUVmax OS p=0.025 The SUVmax of the primary tumor was an independent prognostic factor for OS by a multivariate analysis
21764107 SUVmax DFS p=0.049 The disease-free survival (DFS) rates of patients exhibiting a high SUVmax of the primary tumor were significantly lower than those of patients exhibiting a low SUVmax of the primary tumor
21764107 SUVmax OS p=0.039 The overall survival (OS) rates of patients exhibiting a high SUVmax of the primary tumor were significantly lower than those of patients exhibiting a low SUVmax of the primary tumor
21741077 Beclin 1 survival A high Beclin 1 reactivity occurred in 18.1% of endometrial adenocarcinomas studied and was associated with a poor 5-year survival
21616994 GDF-15 DFS High GDF-15 was also an independent predictor of poor disease-specific and recurrence-free survival.
33635467 BMP-10 OS HR: 8.655, 95% CI 1.098-68.215 p=0.020 BMP-10 expression ( were independent risk factors for the OS of such patients.
21552210 low p21 and high survivin+microsatellite instability survival hazard ratio=7.8 p<0.0001 With multivariate analysis, combined survivin, p21 and microsatellite instability overshadowed all other variables. Patients in which any of these features had favorable values had an excellent prognosis, in contrast to those with either high survivin or low p21
21552210 low p21 and high survivin+microsatellite instability survival hazard ratio=5.6 p=0.01 Combined high survivin and low p21 values and microsatellite instability high identified a small subgroup with an especially poor prognosis
21505452 Tetraspanin CD151 RFS p=0.036 In multivariate analyses, CD151 was significant for RFS in triple negative (ER, PR and HER-2 negative) tumours (88/131)
21505452 Tetraspanin CD151 DSS p=0.033 In multivariate analyses, CD151 was significant for DSS in triple negative (ER, PR and HER-2 negative) tumours (88/131) DSS (P=0.036 and 0.033, respectively)
21468050 HE4 OS p=0.04 In multivariate analysis, sHE4 levels retained its significance as an independent prognostic factor for poor OS
21468050 HE4 PFS p=0.04 In multivariate analysis, sHE4 levels retained its significance as an independent prognostic factor for shorter PFS
21468050 HE4 DFS p=0.01 In multivariate analysis, sHE4 levels retained its significance as an independent prognostic factor for decreased DFS in the subgroup of patients with poorly differentiated ECs
21242118 Stathmin DFS p≤0.002 High Stathmin expression was associated with poor disease-specific survival both in curettage and hysterectomy specimens.
21242118 Stathmin DFS/type II p =0.002 When analyzing the endometrioid group separately, Stathmin in curettage specimens yielded a significant correlation with disease-specific survival
21242118 Stathmin DFS/typeII p =0.06 When analyzing the endometrioid group separately, Stathmin in hysterectomy specimen yielded a significant correlation with disease-specific survival .
34731191 TET1 survival HR of death = 0.31 (95% CI: 0.11–0.84; p<0.05 After adjusting for age, FIGO stage, and histological type, the Cox proportional hazards regression analysis indicated that TET1high score (>20) is an independent predictor of OS, with higher TET1 expression levels conferring an HR of death = 0.31 (95% CI: 0.11–0.84).
33536036 circulating tumor DNA (ctDNA) DFS HR: 17.43 (95% CI, 1.616-188.3 The DFS was a median of 9 months (ctDNA detected) versus median DFS undefined (ctDNA not detected),
21242118 Stathmin survival HR of 1.68 (95% CI: 1.05–2.67), In multivariate Cox survival analysis, strong expression of Stathmin in curettage showed independent prognostic value with an adjusted HR of 1.68 (95% CI: 1.05–2.67), adjusted for age, FIGO stage, histologic type, and grade
21242118 Stathmin survival HR of 1.68 (95% CI: 1.13–3.35; p=0.02 Strong expression of Stathmin in hysterectomy specimens yielded a similar result with an HR of 1.68 (95% CI: 1.13–3.35;
21231983 ALDH1 DFS p=0.015 Patients with high ALDH1 expression showed poorer prognoses than those with low expression for disease-free survival [DFS]
21231983 ALDH1 OS p=0.010 Patients with high ALDH1 expression showed poorer prognoses than those with low expression for for overall survival [OS]
21174065 inhibin-α subunit PFS p=0.003 The Cox regression led to a model containing three independent terms that were predictive of progression-free survival: inhibin-· expression
21174065 inhibin-α subunit survival p=0.003 Independent prognostic factors for cause-specific survival were inhibin expression
21079294 MSI-H status recurrence-free survival p=0.005 The 5 and 10 year recurrence-free survival rates were 98% and 95% in the MSS/MSI-L vs. 85% and 73% in the MSI-H patients
20874004 E-cadherin survival The hypermethylation of CDH1 promoter, which caused low expression of E-cadherin in endometrial cancer, was associated with not only clinicopathological progress of endometrial cancer but also with the overall 5-year clinical survival rate.
20874004 CDH1 promote methylation OS p=.0215 We also demonstrated a significant difference in the survival curves of the subjects with methylated and unmethylated CDH1 promoters
20874004 CDH1 promote methylation The 5-year survival rates among the subjects with methylated and unmethylated CDH1 promoters were 0.500 (SE = 0.091) and 0.788 (SE = 0.057), respectively.
33449452 MMR protein DFS adjusted hazard ratio [HR] 0.092 Whole pelvic radiotherapy VS no adjuvant therapy
20874004 CDH1 promote methylation The survival rates at the end of study among the subjects with methylated and unmethylated CDH1 promoters were 0.500 (SE = 0.091) and 0.738 (SE = 0.063), respectively. T
20874004 E-cadherin p=.017 We demonstrated significant differences in survival curves between the subjects with high E-cadherin expression and those with low E-cadherin expression
20874004 E-cadherin The survival rates of the subjects with high and low E-cadherin expression levels at the end of study were 0.760 (SE = 0.071) and 0.548 (SE = 0.077), respectively
20874004 E-cadherin The 5-year survival rates among the subjects with high and low E-cadherin expression levels were 0.825 (SE = 0.060) and 0.548 (SE = 0.077), respectively
20715109 HAI-1 DFS p=0.046 The DFS rates of patients exhibiting high HAI-1 were significantly higher than those of patients exhibiting low HAI-1
20715109 HAI-1 OS p=0.050 The OS rates of patients exhibiting high HAI-1 were significantly higher than those of patients exhibiting low HAI-1
20715109 HAI-2 DFS p=0.026 The DFS rates of patients exhibiting high HAI-2 were significantly higher than those of patients exhibiting low HAI-2
20715109 HAI-1 and HAI-2 DFS p=0.019 The DFS rates of patients exhibiting HAI-1 and HAI-2 expression (score 0–1) were significantly higher than those of patients exhibiting low HAI-1
20715109 HAI-2 OS p=0.030 The OS rates of patients exhibiting high HAI-2 were significantly higher than those of patients exhibiting low HAI-2
20715109 HAI-1 and HAI-2 OS The OS rates of patients exhibiting HAI-1 and HAI-2 were significantly higher than those of patients exhibiting low HAI-1
33449452 MMR protein DFS adjusted HR 0.18 chemotherapy combined with radiotherapy VS no adjuvant therapy
20686370 YT521 PFS p=0.003 In univariate analyses, higher levels of YT521 exon6-retention mRNA were correlated to a poorer progression-free survival
20686370 YT521 PFS p=0.019 In multivariate analyses , higher levels of YT521 exon6-retention mRNA were correlated to a poorer progression-free survival
20686370 YT521 OS p=0.036 The negative YT521 protein expression was correlated to poorer overall survival
20686370 YT521 DFS p=0.034 The negative YT521 protein expression was correlated to disease-specific survival
20565904 HIF-1alpha survival p=0.044 Perinecrotic HIF-1alpha expression was also prognostic
20565904 HIF-1alpha survival In multivariate Cox regression, perinecrotic HIF-expression emerged as an independent prognostic factor.
20077528 L1CAM RFS p<0.0001 There was a statistically significantassociation between L1CAM expression and poorer RFS
20005452 MSI DFS hazard ratio [HR] 3.25, 95% confidence interval [CI] 1.01-10.49 p=0.048 In early stages MSI provided additional significant predictive information independent of traditional prognostic and predictive factors (age, stage, grade, and vascular invasion) for disease-free survival
20005452 MSI CSS HR 4.20, 95% CI 1.23-14.35 p=0.022 In early stages MSI provided additional significant predictive information independent of traditional prognostic and predictive factors (age, stage, grade, and vascular invasion) for cancer-specific survival
20005452 MSI DFS HR 3.54, 95% CI 0.93-13.46 p=0.064 In early stages MSI was marginally significant for local disease-free survival
33449452 MMR protein DFS adjusted HR 25 Whole pelvic radiotherapy vs. no adjuvant therapy/vaginal brachytherapy)
19855378 p53 RFS p=0.02 Tumors with p53 overexpression were associated with a significantly inferior progression-free survival compared with those that lacked p53 overexpression (3-year progression-free survival were 94% in patients with no p53 overexpression, and 52 % in patients with p53 overexpression;
19855378 p53 DFS p=0.003 Tumors with p53 overexpression were associated with a significantly inferior disease-specific survival compared with those that lacked p53 overexpression (3-year disease-specific survival were 100% in patients with no p53 overexpression, and 54% in patients with p53 overexpression;
19800606 DNA ploidy survival Patients with DNA aneuploid tumors had significantly poorer survival, adjusted for established clinicopathologic prognostic factors.
19650860 RFP OS p=0.0011 Positive RFP expression significantly predicted poorer OS compared with negative expression
19650860 RFP PFS p<0.0001 Positive RFP expression significantly predicted poorer PFS compared with negative expression
19509570 p53 survival OR, 3.0; 95% CI, 1.0-8.7 p=0.0437 P53 also had an independent prognostic value in multivariate analysis, with all prognostic factors for death caused by disease
19411095 intra-tumoralCD8(+) T-lymphocytes OS HR 0.48, 95% C.I. 0.26-0.89 p=0.019 In multivariate analysis, high numbers of CD8(+) T-lymphocytes had an independent prognostic impact for overall survival in the entire cohort
19411095 intra-tumoralCD8(+) T-lymphocytes OS HR 0.17, 95% C.I. 0.08-0.36 p<0.001 In multivariate analysis, high numbers of CD8(+) T-lymphocytes had an independent prognostic impact for overall survival in type II endometrial cancer
19411095 intra-tumoralCD8(+)/FoxP3(+) ratio type I HR 0.44, 95% C.I. 0.23-0.84 p=0.013 A high CD8(+)/FoxP3(+) ratio was independently associated with improved survival in type I endometrial cancer
19411095 intra-tumoralCD45R0(+) lymphocytes OS HR 0.42, 95% C.I. 0.19-0.93 p=0.033 CD45R0(+) lymphocytes were an independent factor for improved OS
33448001 NLR OS HR = 1.06 p<0.001 The results of the univariate analysis indicate a statistically significant correlation between the value of NLR and 5-year OS
19396818 EphA2 DSS p=.04 High EphA2 expression were independent predictors of poor DSS.
19396818 EphA2 DSS p<.001 On univariate analysis of all patients, high EphA2 expression was associated significantly with shorter disease-specific survival (DSS)
19194826 osteopontin DFS hazard ratio = 3.18 p=0.035 By Cox multivariate analysis, osteopontin positivity was an independent prognostic factor for disease-free survival
19133508 Ki-67 survival p<0.05 Survival analysis showed that cases Ki-67 < or =35% VS Ki-67 > 35%
19110306 Cathepsin-B DFS p=0.034 Positive Cathepsin-B expression was also inversely related to Disease-free Survival in univariate analysi
19110306 Cathepsin-B OS p=0.035 Positive Cathepsin-B expression was also inversely related to Overall Survivall in univariate analysi
19110306 Cathepsin-B DFS p=0.022 Positive Cathepsin-B expression was also inversely related to Disease-free Survival in multivariate analysis
19110306 Cathepsin-B OS p=0.035 Positive Cathepsin-B expression was also inversely related to Overall Survivall in multivariate analysis
19108875 progesterone receptor (PR)-A survival OR 4.2, 95% CI 1.32-13.33) p=0.015 Absence of PR-A appeared to be an independent prognostic factor for relapse of disease using multivariate analysis
19108875 ER-alpha death status OR 7.28, 95% CI 1.42-37.25), p=0.017 Absence of ER-alpha was independently related to death of disease
33448001 NLR PFS HR = 1.054 p<0.001 The results of the univariate analysis indicate a statistically significant correlation between the value of NLR and 5-year PFS
18055714 CRP OS p<.001 In a univariable survival analysis, serum CRP levels, tumor stage, tumor grade, and age at diagnosis were associated with disease-free and overall survival
18055714 CRP DFS p=.001 In a multivariable Cox regression model, serum CRP levels were independent prognostic factors for disease-free
18055714 CRP OS p=.004 In a multivariable Cox regression model, serum CRP levels were independent prognostic factors for overall survival.
17890888 c-erb-B2 survival p=0.047 Patients with cytoplasmic c-erb-B2-positive tumors had a significantly shorter survival
17582475 FOLR1 PFS p=0.016 A shorter progression-free survival was noted in patients with FOLR1 overexpression
17582475 FOLR1 PFS H.R. 2.14; 95% CI 1.07-4.28 Multivariate Cox regression analysis revealed that patients with FOLR1 overexpression had a shorter progression-free survival even when controlling for stage, grade, myometrial invasion and adjuvant chemotherapy.
17513511 BNIP3 survival p=0.05 High BNIP3 was associated with poor survival in univariate
17513511 BNIP3 survival p=0.03 High BNIP3 was associated with poor survival in multivariate
17403429 GPR30 survival 65.2% vs 100% p=.005 In patients with GPR30 overexpression, survival was significantly poorer
17117179 Indoleamine 2,3-dioxygenase PFS p=0.001 Even in patients with early-stage disease (International Federation of Gynecology and Obstetrics I/II, n = 64,the PFS for IDO2+/3+ was significantly poor compared to that for IDO-/1+
33448001 NLR OS HR = 2.6 The results of a multivariate analysis including age, histologic grade and Bokhman type have shown that NLR is the only independent prognostic factor of OS
17117179 Indoleamine 2,3-dioxygenase PFS p=0.020 On multivariate analysis, IDO expression was an independent prognostic factor for PFS
17117179 Indoleamine 2,3-dioxygenase OS p=0.002 Patients with high IDO expression had significantly impaired overall survival
17117179 Indoleamine 2,3-dioxygenase PFS p=0.001 Patients with high IDO expression had significantly impaired progression-free survival (PFS)
17108150 ephrinB2 survival p<0.01 There was a significant difference between the 60-month survival rates of the 34 patients with high or low histoscores and mRNA levels of ephrinB2,
17108150 EphB4 survival p<0.05 There was a significant difference between the 60-month survival rates of the 34 patients with high or low histoscores and mRNA levels of EphB4.
17065588 versican DFS p<0.0001 The disease-free survival (DFS) and overall survival (OS) rates of patients exhibiting high stromal versican expression were significantly lower than those of patients exhibiting low stromal versican expression
17065588 versican OS The overall survival (OS) rates of patients exhibiting high stromal versican expression were significantly lower than those of patients exhibiting low stromal versican expression
17023034 YKL-40 PFS p=0.004 At 5 years' follow-up, the PFS rate was 80% for patients with YKL-40<80 ng/mL compared with 43% for patients with YKL-40>80 ng/mL
17023034 YKL-40 OS p=0.047 The 5-year OS rate for patients with YKL-40<80 ng/mL was 79% compared with 48% for patients with YKL-40>80 ng/mL
16999816 PRA DFS p=0.0258 In multivariate analysis demonstrated that an absence of PRA immunoreactivity was an independent risk factor in disease-free survival of the patients
33448001 NLR PFS HR = 2.6 The results of a multivariate analysis including age, histologic grade and Bokhman type have shown that NLR is the only independent prognostic factor of PFS
16999816 PRA DFS p=0.0009 Patients with negative PRA in these carcinoma tissues were associated with a significantly poorer prognosis than those of PRA-positive cases at disease-free survival.
16999816 PRA OS p=0.0098 Patients with negative PRA in these carcinoma tissues were associated with a significantly poorer prognosis than those of PRA-positive cases at overall survival.
16999816 PRB DFS p=0.0005 The absence of either one or both of these two PR isoforms was associated with a significantly poorer prognosis at disease-free survival
16999816 PRA DFS p=0.0005 The absence of either one or both of these two PR isoforms was associated with a significantly poorer prognosis at disease-free survival
16854456 CD105 grade p=0.02 Multivariate analysis showed that MVD determined by CD105 correlated significantly and independently with OS
16854456 CD105 OS p=0.01 With CD105 staining, the 5-year OS rates for patients with the highest MVD count (>or=75%) were significantly poorer than the remaining two groups
16854456 CD105 p=0.01 With CD105 staining, the 5-year OS rates for patients with the highest MVD count (>or=75%) were significantly poorer than the remaining two groups (P=0.01 for both).
16837029 LDH-5 survival LDH-5 was one of the most powerful and independent prognostic variables.
16803534 E-cadherin, alpha-catenin, and beta-catenin survival in grade 1-2 p=0.02 Combined positive E-cadherin, alpha-catenin, and beta-catenin expression was an independent positive prognostic factor for survival in patients with grade 1-2 carcinomas
16710036 HER-2 OS p=.012 By multivariate analysis HER-2 expression in the presence of amplification correlated with overall survival,
33419819 PLB OS HR = 1.001 p=0.011 The results of Cox proportional hazard analysis in our group of aEC patients indicate that the correlation between PLR and 5-year OS
16710036 HER-2 OS p=.0001 Overall survival was significantly shorterin patients who overexpressed (median, 5.2 years) and/or showed amplification of HER-2 (median, 3.5 years) versus those that did not (median of all cases, 13 years).
16564917 Twist survival hazard ratio, 5.12 p=.023 Cox multivariate analyses revealed that only Twist was an independent predictor of patient survival
16445666 cyclin H survival p<0.05 When analyzed with Cox hazard model, the expression of cyclin H were detected as independent factors related to patient survival
16311121 Aurora B survival p=.0135 Patients with Aurora B–positive carcinoma showed poor prognosis compared with those with Aurora B–negative carcinoma
16243811 14-3-3sigma DFS p=0.0321 In multivariate analysis using the Cox proportional hazards model, absence of 14-3-3sigma turned out to be statistically independent risk factor in disease-free survival in patients with early-stage disease
16243811 14-3-3sigma OS p=0.0191 In multivariate analysis using the Cox proportional hazards model, absence of 14-3-3sigma turned out to be statistically independent risk factor in overall survival even in patients with early-stage disease
16080017 skp2 survival The high level of skp2 expression (LI> or =20%) was significantly correlated with the patients' poor survival.
16033094 S100+ DC survival In uni- and multivariate analysis, DC infiltration proved to be a significant prognostic marker for adjusted survival but not for overall survival.
15938112 HER-2+Ki-67 survival Combination of HER-2 overexpression with a high level of Ki-67 is particularly unfavourable (5-year survival--43%).
15790435 ATP7B OS/PFS p<0.01 The patients with ATP7B-positive tumors had a worse prognosis than that with ATP7B-negative tumors in overall survival and disease-free survival, respectively
33419819 PLB PFS HR = 1.001 p=0.011 The results of Cox proportional hazard analysis in our group of aEC patients indicate that the correlation between PLR and 5-year PFS
15755004 DNA ploidy survival DNA ploidy was the stronger independent predictor factor for survival.
15720416 MCM7 survival p=0.04 MCM7 was found to be an independent prognostic factor by multivariate analysis
15720416 MCM7 survival p=0.03 Poor survival was observed in patients with endometrial carcinoma with a high MCM7 index
15328195 E-cadherin OS hazard ratio (HR), 0.59; 95% confidence interval (CI), 0.34-1.03 p=0.066 On multivariate Cox regression, a higher E-cadherin expression score was associated with decreased overall mortality
15328195 E-cadherin disease progression HR, 0.28; 95% CI, 0.10-0.77 p=0.014 On multivariate Cox regression, a higher E-cadherin expression score was associated with disease progression
15240536 Intratumoral CD8+ T lymphocytes survival p=0.025 Multivariate analysis revealed that the number of intraepithelial CD8(+) T lymphocytes at the invasive border were the only independent predictors of survival
15240536 Intratumoral CD8+ T lymphocytes OS p=0.027 Patients with >10 CD8(+) T lymphocytes/high-power field within the tumor epithelium at the invasive border displayed improved overall survival compared with patients with fewer intraepithelial CD8(+) T lymphocytes (87 and 50%, respectively).
15225093 CD171 disease progression L1 expression was correlated with disease progression even in patients with Stage I endometrioid-type endometrial tumors, identifying them as high-risk patients on preoperative curettage specimens.
15225093 CD171 survival p<0.0001 L1 was positive in 20 out of 72 endometrial carcinomas and was again found to be a bad prognostic factor for patient survival
15218296 placental leucine aminopeptidase survival (odds ratio, 12.8; 95% confidence interval, 2.84-58.8; p<0.01) Multivariate analysis demonstrated that strongly immunoreactive P-LAP is independent prognostic factors
34473724 p16 survival 0.2 (0.0–0.9) p=0.033  In the interaction analysis, molecular subclass significantly modified the prognostic effect of p16 hyperexpression, which showed a stronger negative effect on survival in NSMP as compared to MMR-D
33419819 PLB PFS HR=0.22; 95%CI=0.093-0.52 p<0.001 A strong correlation was observed between the density of PLB and progression-free survival (very low, low vs. intermediate, high;
15139995 vascular invasion survival HR 4.3 p<0.0001), Vascular invasio showed independent significance
15139995 tumour cell proliferation (Ki67) survival Tumour cell proliferation measured by Ki67 expression all had independent prognostic influence in this population-based study.
15084841 p53 index survival p=0.0001 Patients with strongly p53 immunoreactive tumors (p53 index >or =50%) had a significantly worse outcome than patients with weakly immunoreactive (p53 index > or =5% and <50%) or p53-negative (p53 index <5%) tumors
15084841 p53 index survival p=0.02 p53 immunostaining was of prognostic significance in the subset of patients with endometrioid carcinomas, but not in patients with clear cell or papillary serous carcinomas.
15068320 DNA ploidy survival p<0.001 DNA ploidy was highly significant prognostic factors
15068320 DNA ploidy survival p=0.001 The multivariate analysis included p53 expression, DNA ploidy, degree of differentiation and age. DNA ploidy was the only factor with preserved significance.
15051772 P-cadherin survival p<.05 In univariate survival analyses, all adhesion markers influenced survival significantly
15051772 P-cadherin survival p<.001 P-cadherin (high expression; 16%), had significantly reduced survival compared with the remaining samples
14981988 DNA ploidy survival In univariate analysis, DNA ploidy was correlated significantly with survival.
14981988 DNA ploidy OS In multivariate analysis DNA ploidy (diploid versus nondiploid; RR 5.1) remained significant independent predictors of overall survival.
33419819 PLB OS HR=0.259; 95%CI=0.091-0.73 p=0.011 A strong correlation was observed between the density of PLB and overall survival (very low, low vs. intermediate, high;
14629267 CD105/endoglin-MVD survival p=0.036 Tumours within the two groups defined by the upper and lower quartiles for CD105/endoglin-MVD were both significantly with reduced survival as compared with the intermediate groups.
12926169 preoperative serum CA 125 survival In univariate analysis, DNA ploidy, S-phase fraction, serum CA 125 level and peritoneal cytological findings correlated significantly with survival.
12926169 CA 125 OS In multivariate analysis, peritoneal cytology (benign versus malignant), grade (1 + 2 versus 3) and preoperative serum CA 125 concentration (< or = 25 U/ml versus > 25 U/ml) remained significant independent predictors of overall survival.
12895227 p53 survival p=0.043 p53 expression were significantly related to a poor prognosis in the Kaplan-Meier method using the log-rank test
12866376 IGF-IR survival p<or=.05 Longer survival was observed for patients with low level IGF-IR (< 10% of cells)
12798703 Elf-1 survival p<0.01 Survival data were available for all patients and demonstrated that Elf-1 expression was significantly associated with poor prognosis
12798703 Elf-1 survival p<0.01 Scoring on the basis of the percentage of nuclear-positive cells indicated that nuclear Elf-1 expression was significantly associated with clinical outcome .
12792921 cyclin A survival Multivariate analysis showed that the factors for poor prognosis were cyclin A positivity.
12747468 CD44 variant 6 survival Univariate analysis revealed that each CD44 was a prognostic determinant in the patients with EC
12684410 KAI1 survival p=0.0042 It was also found that patients with KAI1-negative tumors had a lower survival rate than those with KAI1-decreased or positive tumors
33338506 ER/PR outcome 5-year DSS = 75.9-83.3%); three subgroups with distinct clinical outcomes were identified: 0-10% of ER/PR expression with, unfavorable outcome
12556100 DNA topoisomerase II-alpha (Ki-S1) survival p<or=0.05 In the Cox regression analysis, Topoisomerase II-alpha (Ki-S1), serosal and/or adnexal involvement, and lymph node metastasis expression were the only variables with independent prognostic impact
12525874 CaMKIV survival p=0.04 CaMKIV expression was significantly associated with clinical outcome (no evidence of disease versus died of disease;
12115383 Ribosomal DNA methylation survival p<0.0001 Both disease free survival and overall survival were significantly worse for patients with low-level rDNA methylation
12115383 Ribosomal DNA methylation survival p<0.0001 Among the subpopulation of patients with endometrial carcinoma for whom the use of adjuvant therapy is most controversial (148 women with Stage I-II endometrioid tumors), survival was significantly worse for the patients with rDNA-low tumors
12115383 Ribosomal DNA methylation PFS hazard ratios, 11.0 and 26.3 p<0.01 Using multivariate analyses, tumor rDNA level was the only significant prognostic factor for both disease free survival and overall survival
11903603 MUC1 survival p=0.04 Cytoplasmic MUC1 positivity was significantly associated with poor prognosis
11903603 MUC1 PR expression MUC1-negative carcinomas were associated with PR expression and an improved survival
11745191 VEGF/KDR stage I VEGF and VEGF/KDR were the only independent prognostic variables for patients with Stage I endometrioid adenocarcinoma.
11745191 VEGF/KDR survival p<0.01 In multivariate analysis, disease stage was the most important independent prognostic factor (P < 0.0001), followed by VEGF/KDR
11745191 VEGF survival p=0.0002 In univariate survival analysis, VEGF were significant prognostic variable.
33338506 ER/PR outcome 5-year DSS = 93.0-93.9%) Three subgroups with distinct clinical outcomes were identified: 20-80% of ER/PR expression with, intermediate outcome
11745191 aMVD survival p=0.001 In univariate survival analysis, aMVD were significant prognostic variable.
11745191 sMVD survival p=0.0009 In univariate survival analysis, sMVD were significant prognostic variable
11520144 EMA PFS p=0.017 In multivariate analysis EMA overexpression was independent prognostic factors for progression-free survival.
11516808 p53 survival p<0.001 Simultaneous p53 and HER-2/neu overexpression made worse the prognostic
11431715 telomerase progression p=.0002 Telomerase activity emerged as the only independent predictor of disease progression
11136569 PAI-1 DFS p=0.005 Elevated expression of PAI-1 was associated with significantly shorter disease-free
11136569 PAI-1 OS p=0.0003 Elevated expression of PAI-1 was associated with significantly overall survival
10999747 Serum soluble fas survival p=0.012 Survival rates in groups with endometrial carcinoma with a serum sFas level < 1.5 ng/ml exceeded those in groups with sFas levels of 21.5 ng/ml
10831352 Flt-4 survival Kaplan-Meier method and univariate analysis showed Flt-4 overexpression to be related to poor prognosis of patients with endometrial carcinomas
10831352 Flt-4 survival Multivariate analysis revealed that Flt-4 overexpression correlated independently with poor survival.
33338506 ER/PR outcome Three subgroups with distinct clinical outcomes were identified: 90-100% of ER/PR expression with, favorable outcome
10656444 p16INK4aa survival p<0.0001 The 5-year survival was 47% for patients with absent/minimal nuclear p16 expression (n = 39) compared with 81% for patients with moderate/high nuclear p16 expression (n = 247;
10656444 p16INK4aa survival hazard ratio of 2.9 (95% confidence interval, 1.3-6.5). In Cox proportional hazards regression analysis, nuclear p16 expression showed an independent prognostic impact in addition to FIGO stage, age, Ki-67 expression, and microvessel density, with an adjusted hazard ratio of 2.9
10600302 MIB-1 survival p<0.001 By multivariate analysis, only MIB-1 staining was shown to be independent prognostic indicators predictive of survival.
10452508 anti-repp 86 death p=.001 Anti-repp 86 LI emerged as relevant predictors of mortality.
10202671 HER-2/neu survival p=0.002 Using the proportional hazards model of survival, amplification was found to have significant negative predictive value beyond stage, grade, and cell type
9934583 Ki-S4 PA overall survival p=0.008 Univariate analysis showed that Ki-S4 PA was independent prognosticators for adjusted overall survival in multivariate analysis.
9829742 Ki-67 survival hazard ratio, 8.7; 95% confidence interval, 3.0-25.2 In Cox regression analysis,Ki-67 was the only variables with independent prognostic impact
9648591 PR DFS p=0.0025 PR immunohistochemistry of endometrial carcinoma was statistically correlated with disease-free survival (living vs dead,
9648591 ER DFS p=0.032 ER immunohistochemistry had significant correlations with disease-free survival
9648591 ER survival p=0.026 Multivariate analysis of PR/ER immunohistochemistry, stage, grade, and myometrial invasion showed that the PR immunohistochemistry was a significant prognostic factor for survival
33237570 P53 RFS 89.7% (95%CI 88.0–91.4) vs 66.6% (95%CI 61.3–71.9) p<0.001 The 3-year RFS was 89.7% in the low-value group and 66.6% in the high-value group , while the 3-year OS was 93.9% and 76.4%, respectively
9646853 HER-2/neu OS p=0.025 In a multivariate analysis, a statistically significant correlation was found between the level of expression of HER-2/neu oncogene and overall survival
9570981 GST-pi survival p<0.05 The prognosis of patients with a GST-pi-positive tumor was significantly poorer than that of those with a GST-pi-negative tumor
9570981 c-Jun survival p<0.05 The patients with c-Jun-positive tumor also had a significantly worse prognosis than those with c-Jun-negative tumor
9422988 p53 survival p=0.035 Patients with p53 mutations had a significantly worse prognosis than those without mutations
9422988 p21 survival p=0.074 Patients with p21 expression tended to have a better prognosis than those without p21 expression
9340973 growth fraction DFS Multivariate and univariate analysis exhibited growth fraction rate to be independent predictors of a disease-free survival.
9340973 growth fraction OS Cox multivariate regression showed growth fraction to be independent predictors of overall survival
9218009 CA15.3 survival In multivariate analysis, CA15.3 was highly significant and had a larger hazard ratio.
8909315 S-phase fraction (SPF) survival p<0.001 In initial analyses, SPF were predictors of poor survival
8909315 Ki-67 survival p<0.05  In initial analyses, Ki-67 were predictors of poor survival
33237570 P53 RFS p<0.001 The 3-year RFS of patients who did not receive adjuvant chemotherapy or radiotherapy was 95.7% and 78.2% between the two groups
8761370 p53 survival p<0.001 Nuclear p53 overexpression was associated with poor survival
8761370 p53 survival p<0.001 cytoplasmic p53 overexpression was associated with better survival
8761370 p53 survival [hazard ratio 4.9 (95% CI 1.3-17.6). p=0.016 In multivariate analysis adjusted for surgical stage, histological grade and type and vascular invasion, nuclear p53 overexpression were independent prognostic factor
8761370 p53 survival [0.25 (0.06-0.98), p=0.047] In multivariate analysis adjusted for surgical stage, histological grade and type and vascular invasion, cytoplasmic overexpression were independent prognostic factors.
8695259 p53 survival p=0.006 Strong p53 expression was highly predictive of poor survival in the univariate analysis
8610771 HER-2/neu survival By multivariate analysis only vascular invasion-associated changes, aneuploidy, and HER-2/neu overexpression were found to independently correlate with survival.
8556702 HER-2/neu survival log-rankp-value0.04 HER-2/neu oncoprotein expression was associated with poor overall survival
8088605 CA 15-3 survival p=0.00025 A statistically significant relationship was demonstrated between CA 15-3 positivity (CA 15-3 > 30 and 50 U/ml) and a shorter survival
8088605 CA 125 survival p=0.0027 A statistically significant relationship was demonstrated between CA 125 (> 65 U/ml) and a shorter survival
7909788 EGFR survival p<0.03 In the serous papillary and clear cell category, EGFR positivity decreased survival from 86 to 27%
33237570 P53 RFS 87.9% (95%CI 85.9–89.9) vs 61.2% (95%CI 55.1–67.3) p<0.001 The 5-year RFS was 87.9% (95%CI 85.9–89.9) in the low-value group and 61.2% (95%CI 55.1–67.3) in the high-value group
7909788 EGFR survival p<0.04 For patients with endometrioid adenocarcinoma, evidence of EGFR overexpression decreased survival from 89 to 69%
7631667 colony-stimulating factor 1 survival p=0.04 Mean colony-stimulating factor 1 levels (9.6 vs 7.7 ng/ml, p = 0.04) was higher in patients with poor prognosis than in those with good prognosis
1361478 HER-2/neu PFS p<0.0001 The strong staining group was distinct from the nonstaining group in predicting progression-free survival.
1361478 HER-2/neu PFS p=0.028 The mild staining groups were distinct from the nonstaining group in predicting progression-free survival.
1361478 HER-2/neu OS p<0.0001 strong overexpression was associated with a poor (51%) overall survival
1361478 HER-2/neu PFS p=0.0003 Multivariate analysis revealed that intense overexpression had independent significance in predicting progression-free
1361478 HER-2/neu OS p<0.0001 Multivariate analysis revealed that intense overexpression had independent significance in predicting OS
1361478 HER-2/neu DFS p=0.0007 In stage I patients (203), the 5-year progression-free survival was 62% for the strong and 97% for the nonstaining groups
1361478 HER-2/neu OS p<0.0001 Multivariate analysis revealed that intense overexpression had independent significance in predicting overall survival
1361478 HER-2/neu DFS p=0.0003 Multivariate analysis revealed that intense overexpression had independent significance in predicting progression-free
33237570 P53 OS (95%CI 92.5–95.3) VS (95%CI 71.4–81.4) p<0.001 The 3-year OS presented as 93.9% (95%CI 92.5–95.3) and 76.4% (95%CI 71.4–81.4)
1361478 HER-2/neu PFS p<0.0001 The strong staining groups were distinct from the nonstaining group in predicting progression-free survival.
1342555 PR survival From 54 women with EC-7 died during 3 years period of time. From these 7, only one was with elevated concentrations of both ER and PR. 5 women were with negative PR and in 3-negative both ER and PR.
36562226 B7 homolog 4 (B7-H4) Univariate analysis showed that the 5-year RFS and DSS of patients with different age, tumor grade, surgical-pathological stage, pathological type, depth of muscular invasion, lymphovascular space invasion, and molecular subtype were significantly different.
36562226 B7-H4 In patients with low-density CD8+ T lymphocytes endometrial cancer, positive expression of B7-H4 protein was an independent factor for 5-year RFS,, but it was not an independent factor for 5-year DSS.
36721236 SLERT P = 0.006 Patients with high SLERT had shorter survival time than those with low SLERT
36251972 p53 OS,DFS P <0.001 Analysis of follow-up period revealed that EC with abnormal p53 IHC expression, high pirh2 and positive L1CAM expression exhibited a potent relation with tumor relapse, shorter overall survival and disease-specific survival
36251972 Pirh2 OS,DFS P <0.001 Analysis of follow-up period revealed that EC with abnormal p53 IHC expression, high pirh2 and positive L1CAM expression exhibited a potent relation with tumor relapse, shorter overall survival and disease-specific survival
36251972 L1CAM OS,DFS P <0.001 Analysis of follow-up period revealed that EC with abnormal p53 IHC expression, high pirh2 and positive L1CAM expression exhibited a potent relation with tumor relapse, shorter overall survival and disease-specific survival
35804040 PD-L1 OS p = 0.038 PD-L1 positivity was associated with improved overall survival
35804040 PD-L1 TPS p < 0.0001 PD-L1 correlated with higher CD8 + T-cell density when evaluated by either TPS (p = 0.02) or CPS
33237570 P53 OS (95%CI 91.4–94.4) VS(95%CI 62.9–75.1) p<0.001 The 5-year OS was 92.9% (95%CI 91.4–94.4) and 69% (95%CI 62.9–75.1) between the two groups
36881401 TARS OS P = 0.0012 TARS was significantly highly expressed in serous type, G3 grade, and deceased status. Significant association was between high TARS expression with poor overall survival 
34689225 Tertiary lymphoid structures P = 0.003 The absence of TLS was independently associated with tumor progression (HR, 0.154; 95% CI, 0.044–0.536).
34689225 Tertiary lymphoid structures PFS P = 0.01 CD20+ B cells numbers were positively correlated with other TLSs. The larger number of CD20+ B cell was associated with better PFS.
35429348 L1CAM P = .019 In multivariate survival analysis, L1CAM expression was significantly associated with poor outcome (HR: 2.03, P = .019), potentially through an indirect effect, mediated by its influence on response to chemotherapy.
35866777 KRT15 P = .018 Elevated KRT15 protein expression was correlated more advanced International Federation of Gynecology and Obstetrics stage.
35866777 KRT15 DFS P<0.05 Multivariate Cox's regressions showed that tumor KRT15 protein (high vs low) was independently correlated with poor DFS (P = .045) and OS (P = .043).
35469683 Apparent diffusion coefficient (ADC) Compared with non-CR patients, CR patients had significantly higher minADC and 10th and 25th ADC percentiles at the second follow-up (P = 0.008, 0.039, and 0.034, respectively) and higher minADC, older age, lower HE4 level, and higher overweight rate at the third follow-up (P = 0.001, 0.040, 0.021, and 0.004, respectively).
35611517 HER2 DFS and OS P = .014 HER2 IHC revealed a heterogeneous staining pattern, such as intense complete membranous in solid areas, and basolateral in papillary and glandular areas. HER2 gene amplification was significantly associated with shorter overall (P = .005) and disease-free (P = .014) survival.
37141412 LY6K p= 0.0032 LY6K expression is 8.25× higher in UCEC compared to normal uterine tissue, and this high expression is associated with poor survival with a hazard ratio of 2.42 ).
34420090 CTNNB1 DFS p=0.010 Tumours with CTNNB1 exon 3 mutation were associated with reduced disease-free survival
33235117 TWIST1 DFS HR, 2.361; 95% CI, 1.081–5.159 p = .03 More importantly, multivariate analysis showed that high TWIST1 expression was independent predictors of worse DFS in patients with type I ECs.
33208911 LGALS3BP survival High LGALS3BP expression was observed in human EC tissue, which indicated a poor prognosis.
33197888 PPARγ(-)/ERRα(+) OS p<0.001 EC patients with PPARγ(-)/ERRα(+) had the worst overall survival
33197888 PPARγ(-)/ERRα(+) DFS EC patients with PPARγ(-)/ERRα(+) had the worst disease-free survival rates
32920817 [ER + PR]/[P53 + Ki67] RFS p<.001 The 3-year recurrence-free survival (RFS) and overall survival of patients in the low-ratio group were 54.1% and 66.8%
32920817 [ER + PR]/[P53 + Ki67] RFS p<.001 The 3-year recurrence-free survival (RFS) and overall survival of patients in the high-ratio group were 94.9% and 97.9%
32920817 [ER + PR]/[P53 + Ki67] RFS HR=0.541(95% confidence interval [CI] 51.3%–56.9%) 3‐year RFS
32920817 [ER + PR]/[P53 + Ki67] RFS HR= 95% CI 93.7%–100% p<.001 3‐year RFS
32920817 [ER + PR]/[P53 + Ki67] RFS HR= (95% CI 47.5%–52.9%) p<.001 The 5‐year RFS
32920817 [ER + PR]/[P53 + Ki67] RFS HR= (95% CI 91.3%–100%) p<.001 The 5‐year RFS
34420090 CTNNB1 OS p=0.807 Tumours with CTNNB1 exon 3 mutation no impact on OS
32920817 [ER + PR]/[P53 + Ki67] OS HR=0.668 (95% CI 63.5%–70.1%) p<.001 the 3‐ year OS
32920817 [ER + PR]/[P53 + Ki67] OS HR=0.979 (95% CI 89.1%–100%) p<.001 the 3‐ year OS
32920817 [ER + PR]/[P53 + Ki67] OS HR=0.598 (95% CI 56.5%–63.1%) p<.001 the 5‐year OS
32920817 [ER + PR]/[P53 + Ki67] OS HR= 0.973(95% CI 86.6%–100%) p<.001 the 5‐year OS
32901849 CDK9 PFS Kaplan-Meier survival curve showed that compared with patients with endometrial cancer in the CDK9 low expression group (CDK9 staining score ≤2), those in the CDK9 high expression group (CDK9 staining score ≥3) had significantly shorter PFS , and the differences were statistically significant (P<0.0001, based on the log-rank test)
32901849 CDK9 OS Kaplan-Meier survival curve showed that compared with patients with endometrial cancer in the CDK9 low expression group (CDK9 staining score ≤2), those in the CDK9 high expression group (CDK9 staining score ≥3) had significantly shorter OS, and the differences were statistically significant (P<0.0001, based on the log-rank test)
32829673 VDAC2 survival p=0.03 Multivariate analysis identified the VDAC2 mRNA levels as well as VDAC2 protein level as independent prognostic factors.
32829673 VDAC OS p<0.05 Kaplan-Meier analysis indicated that high expression of all VDAC genes or high VDAC2 protein level predicted poor overall survival.
32829673 VDAC1 OS 4.85 [1.99–11.85] p=0.00052 Multivariable Cox regression analyses of VDAC1 mRNA expression and clinicopathological factors influencing patients’ survival(OS).
32829673 VDAC2 OS 2.17[ 1.74–5.06] p=0.031 Multivariable Cox regression analyses of VDAC1 protein expression and clinicopathological factors influencing patients’ survival(OS).
34410950 cytoplasmic LCOR mean OS p=0.029 Patients with low cytoplasmic LCOR expression had a significantly worse OS than those with high expression
32630554 MSX1 survival p=0.023 A significant better survival for patients with an MSX1 expression in more than 10% of the tumor cells was observed for endometrioid endometrial carcinomas (21.3 years median survival (MSX1-positive) versus 17.3 years (MSX1-negative)).
32468249 Co-Expression of Mesothelin and CA125 OS hazard ratio: 3.32 p=0.039 In multivariate analysis,positive co-expression was the worst prognostic factor for OS
32468249 Co-Expression of Mesothelin and CA125 PFS p=0.043 PFS of patients with positive co-expression were worse
32468249 Co-Expression of Mesothelin and CA125 OS p=0.012 OS of patients with positive co-expression were worse
32451988 KLF5 survival HR 4.72, CI.95 1.61–13.89 p<0.05 In multivariate Cox regression analyses KLF5 cytoplasmic H-score were still predictive of poor overall survival outcome also after adjusting for woman’s age, obesity, diabetes mellitus, FIGO stage, and tumor grading
32451988 KLF11 OS HR 3.04, CI.95 0.99–9.36 p=0.053 In multivariate Cox regression analyses KLF11 nuclear H-score were still predictive of poor overall survival outcome also after adjusting for woman’s age, obesity, diabetes mellitus, FIGO stage, and tumor grading
32451988 KLF11 DFS HR 3.48, CI.95 1.55–7.78 p<0.05 In univariate Cox regression analysis and a high KLF11 nuclear Hscore resulted to be significantly predictive of short diseasefree survival , adjusting in multivariate analysis for woman’s age, FIGO stage
32451988 KLF11 DFS 2.59 (CI.95 1.13–5.95) p<0.05 In univariate Cox regression analysis and a KLF11 nuclear H-score resulted to be significantly predictive of short diseasefree survival , adjusting in multivariate analysis for woman’s age, FIGO stage
30684972 RRBP1 OS p=0.001 High levels of expression of RRBP1 were strongly correlated with poor overall survival (OS)
30684972 RRBP1 DFS p<0.001 High levels of expression of RRBP1 were strongly correlated with disease-free survival (DFS)
34339705 TMEFF2 DFS p<0.001 positive TMEFF2 expressing patients had poor DFS
30661222 STC2 RFS p=0.037 Kaplan-Meier analyses confirmed that patients with high-expression of STC2 had a significantly poorer RFS than those with negative or low STC2 expression
30585737 miR-142 survival p=0.0149 Low-level miR-142 was correlated with poor prognosis of EC patients
30577833 ELR OS p=0.004 Higher values of ELR was correction with worse OS
30577833 ENLR OS p=0.010 Higher values of ENLR was correction with worse OS
30577833 ELR OS HR = 2.9 p=0.017 ELR ≥ 0.1 was correction with shorter OS
30577833 ENLR OS HR = 3.0 p=0.015 ENLR ≥ 0.5 was correction with shorter OS
30561762 MMR status RFS p=.001 The estimated 5-year RFS was 66% for women who had dMMR compared with 89% for those who had iMMR
30561762 MMR status RFS p=.0004 Excluding isolated vaginal recurrences, the difference in 5-year RFS was 73.5% versus 95%, respectively
30561762 MMR status RFS p=.001 Kaplan-Meier survival analysis dMMR has shorter RFS
30556848 LncRNA FER1L4 OS p=0.0071 Kaplan-Meier survival curves showed that overall survival rate in patients with high FER1L4 expression level was markedly higher than those with low FER1L4 expression level

Institutes for Systems Genetics, West China Hospital
     Copyright @ 2023 ISG. All Rights Reserved.